Key result
Hemoadsorption during cardiac surgery reduced acute kidney injury incidence from 39.7% to 28.4% in the SIRAKI02 trial, highlighting potential renal benefits independent of significant cytokine modulation.
Absolute Event Rate: 28.4% vs 39.7%
p-value: p=0.03
Highlights limitations regarding patient selection and baseline cytokine levels in recent trials evaluating hemoadsorption during cardiac surgery.
We read with interest the recent article by Hohn et al., addressing the efficacy of the hemoadsorption technique in managing cytokine elevation following cardiac surgery, with a particular focus on renal outcomes and the evolving role of extracorporeal blood purification.The REC-CAS study on CytoSorb ® and the SIRAKI02 randomized trial on oXiris ® membranes represent pivotal contributions to this field.Yet, they also share limitations that must be carefully considered [1,2].
No takes yet. Share an insight, caveat, or question.
Ramírez‐Guerrero et al. (2024) conducted a letter in Cardiac surgery. Hemoadsorption vs. Standard care was evaluated on Acute kidney injury (AKI) incidence (p=0.03). Hemoadsorption during cardiac surgery reduced acute kidney injury incidence from 39.7% to 28.4% in the SIRAKI02 trial, highlighting potential renal benefits independent of significant cytokine modulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: